Back to Journals » ImmunoTargets and Therapy » Call For Papers

ImmunoTargets and Therapy

ISSN: 2253-1556


The following Article Collections/ Thematic Series are currently open for submissions:

Oral Vaccines for Infectious and or Non-Infectious Diseases

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Oral Vaccines for Infectious and or Non-Infectious Diseases" in ImmunoTargets and Therapy.

Vaccines are biological formulations of antigenic material(s) and excipients capable of inducing protection against one or more infectious or malignant diseases of interest. Next to safe drinking water, vaccines have remained the cornerstone of public health interest as they remain the most cost-effective way to prevent infectious and malignant diseases. Vaccines are most commonly administered by needle injections and only a few are administered through the oral or the nasal routes. Oral vaccines are more advantageous than injection-based vaccines for a number of reasons: including increased safety, ease of administration and compliance, and simpler manufacture and delivery. Additionally, the oral route allows for the development of cellular and humoral immune responses at mucosal and systemic locations to provide a more extensive and long-lasting immunity. Convenient for all ages, oral vaccines can offer immunity against varieties of infectious diseases. 

Edible vaccines, also referred to as food vaccines, plant-based vaccines, or green vaccines, are a group of newly emerging oral vaccines and may later become possible alternatives to cold-chain vaccines, especially for developing countries. The concept of using edible tissues of genetically engineered crops as a manufacturing and delivery system for biologics was first introduced in the early 1990s by Dr. Charles Arntzen and his associates. This plant-based vaccine can be developed against both communicable and non-communicable diseases and can be taken either by eating the edible part of the transgenic crop or by oral administration of the refined protein extract. 

It is essential to invest more research efforts into developing stable oral vaccines as a delivery route. Furthermore, oral vaccines which are grown in antigen-producing plants will eliminate the need for transportation and cold chains, and will overcome the challenges of inaccessibility to vaccines in many rural communities of developing countries. More scientific studies are needed in various aspects of oral vaccine to tackle myriads of human and veterinary diseases. 

We welcome papers covering In silico studies relating to any aspects of epitope identification and oral vaccine design: Immunology and immunological aspects of oral vaccines; Animal models of diseases (communicable and non-communicable) being experimented upon with any form of oral vaccine; Oral and edible vaccines; Implementation Science and management; Oral vaccines for animal and human diseases; and other aspects of oral vaccines. Original research, Commentaries, Letters to the Editor, and Reviews are welcome.

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript. 

Please submit your manuscript on our website, quoting the promo code XYTAJ to indicate that your submission is for consideration in this Article Collection. The deadline for submitting manuscripts is 1 July 2024.

Guest Advisors

Angus Nnamdi Oli, Nnamdi Azikiwe University

[email protected]

Dr. Oli, a trained Pharmacist, is a Reader at Nnamdi Azikiwe University, Awka, Nigeria with expertise in Vaccinology, Immunology, Pharmaceutical Microbiology Quality Assurance and Infectious Disease Researches. He is listed among the first 500 scholars in Nigeria by Scopus for the years 2022 and 2023. He has undergone several trainings including Massive Open Online Courses (MOOC) on Implementation Research (IR) with a focus on Infectious Diseases of Poverty (IDP) organised by African Regional Training Centre, University of Ghana School of Public Health and the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR).

Adekunle Rowaiye, National Biotechnology Development Agency

[email protected]

Dr. Rowaiye is a Veterinarian and Pharmaceutical Biotechnologist. His research interest is in the discovery, design, and evaluation of drug candidates which include small molecules, natural products, peptides, and proteins. Dr Rowaiye has several publications in international journals and he is presently working on the discovery of drug candidates that will retard the aging process and prevent neurodegenerative diseases.

View all papers in this article collection

The Role of Natural Killer Cells in Disease

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "The Role of Natural Killer Cells in Disease" in ImmunoTargets and Therapy.

Natural killer (NK) cells were first identified by Dr. Ronald B. Herberman, who unfortunately passed away several years ago. Since their first identification, it was clear that these cells expressed anti-tumor activity and were initially named natural cytotoxicity (NC) cells, and later as NK cells. Although they respond to danger whilst circulating in the peripheral blood, they can rapidly migrate into sites of immune reactions in peripheral tissues. It is also apparent that whilst responsible for killing tumor cells, they additionally display an immunoregulatory function. Consequently, they react to microbes, particularly virally-infected cells, as well as protecting the immune system by depleting unwanted antigen-presenting cells - which can sometimes be detrimental due to provoking autoimmunity.

Although the therapeutic potentials of NK cells in cancer and to some extent in autoimmune diseases are well established, these cells also play important roles in other diseases which will constitute an important aspect of this Article Collection. This Article Collection aims to explore the involvement and/or therapeutic potentials of NK cells in various diseases. Reviews and original articles from worldwide experts dealing with the role of NK cells in any of the below mentioned fields are highly encouraged to submit their valuable work.

1. Cancers
2. Autoimmune diseases
3. Neurodegenerative diseases
4. Stroke and heart diseases
5. Virus infection, including COVID
6. Other microbial infections
7. Pulmonary diseases
8. Gastrointestinal diseases
9. Musculoskeletal diseases
10. Hematological disorders
11. Skin diseases

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code HUAAS to indicate that your submission is for consideration in this Article Collection. The deadline for submitting manuscripts is 15 July 2024.

Guest advisors

Dr. Azzam A. Maghazachi, Research Department, ImmunoProfiling and Boosting, Oslo, Norway

[email protected]

Dr. Azzam A Maghazachi received a masters degree from New York University Medical School (USA), and a PhD degree in Immunology from the University of Manitoba Medical School (Canada). He completed post-doctoral fellowships at NYU Medical School (USA) and then worked under the supervision of the late Dr. Ronald B. Herberman at the Pittsburgh Cancer Institute. Between 1988-2007, he held several senior positions in various institutes and universities in the USA, Canada and Norway. He was a Professor of Physiology in the faculty of Medicine at the University of Oslo, Norway, and later a professor of Immunology in the college of Medicine, University of Sharjah. Dr. Maghazachi research interests include cancer immunology, autoimmune diseases, chemokines, and drug mechanisms of action. Dr. Maghazachi is an editor or editor-in-chief for more than 10 scientific journals in the fields of Immunology, Oncology and Neuroscience. He has published more than 120 scientific papers as well as book chapters and ebooks.

View all papers in this article collection


Call For Papers


To see where ImmunoTargets and Therapy is indexed online view the Journal Metrics.

What is the advantage to you of publishing in ImmunoTargets and Therapy?

  • It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
  • Unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
  • The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. ImmunoTargets and Therapy has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
  • Many authors have found that our peer reviewer’s comments substantially add to their final papers.

To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution an article publishing charge.

PubMed Central
ImmunoTargets and Therapy is indexed on PubMed Central (title abbreviation: Immunotargets Ther). All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits
If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page.

Yours sincerely
Dr Michael R Shurin
Editor-in-Chief
ImmunoTargets and Therapy

Email: Editor-in-Chief